Abatacept therapy offers promising results for treating juvenile dermatomyositis

by George Washington UniversityScreening, Trial Entry and Outcome. Credit:Arthritis & Rheumatology(2023). DOI: 10.1002/art.42450Juvenile dermatomyositis, a rare but often severe a

Updated on: May 29,2024

Abatacept therapy offers promising results for treating juvenile dermatomyositis

by George Washington UniversityScreening, Trial Entry and Outcome. Credit:Arthritis & Rheumatology(2023). DOI: 10.1002/art.42450Juvenile dermatomyositis, a rare but often severe a

Updated on:May 29,2024

Study finds COVID-19 vaccine not associated with severe disease flare in patients with rheumatic diseases

by American College of RheumatologyCredit: Unsplash/CC0 Public DomainNew research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the

Updated on: June 17,2024

Study finds COVID-19 vaccine not associated with severe disease flare in patients with rheumatic diseases

by American College of RheumatologyCredit: Unsplash/CC0 Public DomainNew research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the

Updated on:June 17,2024

COVID infection may boost antibodies for up to 20 months

If you've already had COVID-19, your natural antibodies may last as long as 20 months, a new study suggests.While this is reassuring, experts are quick to caution that the new findings don't n

Updated on: April 13,2024

COVID infection may boost antibodies for up to 20 months

If you've already had COVID-19, your natural antibodies may last as long as 20 months, a new study suggests.While this is reassuring, experts are quick to caution that the new findings don't n

Updated on:April 13,2024

OX40-positive follicular helper T cells control rheumatoid arthritis

by University of TsukubaCredit: CC0 Public DomainRheumatoid arthritis is a progressive autoimmune disease most frequently characterized by pain, swelling, and stiffness in joints. Increased numbe

Updated on: June 17,2024

OX40-positive follicular helper T cells control rheumatoid arthritis

by University of TsukubaCredit: CC0 Public DomainRheumatoid arthritis is a progressive autoimmune disease most frequently characterized by pain, swelling, and stiffness in joints. Increased numbe

Updated on:June 17,2024

Patients with rheumatic and musculoskeletal conditions vulnerable to long term opioid use

by British Medical JournalCredit: Unsplash/CC0 Public DomainPatients with rheumatic and musculoskeletal conditions are vulnerable to long term opioid use, with up to 1 in 3 of those with rheumato

Updated on: June 15,2024

Patients with rheumatic and musculoskeletal conditions vulnerable to long term opioid use

by British Medical JournalCredit: Unsplash/CC0 Public DomainPatients with rheumatic and musculoskeletal conditions are vulnerable to long term opioid use, with up to 1 in 3 of those with rheumato

Updated on:June 15,2024

A protein's surprising role offers clues to limit graft-vs.-host disease

by Nicole Fawcett,University of MichiganFrom left, Hideaki Fujiwara, M.D., Ph.D.; Grace Chen, M.D., Ph.D.; and Pavan Reddy, M.D. Credit: University of Michigan Rogel Cancer CenterA protein that

Updated on: May 07,2024

A protein's surprising role offers clues to limit graft-vs.-host disease

by Nicole Fawcett,University of MichiganFrom left, Hideaki Fujiwara, M.D., Ph.D.; Grace Chen, M.D., Ph.D.; and Pavan Reddy, M.D. Credit: University of Michigan Rogel Cancer CenterA protein that

Updated on:May 07,2024

A stealthy way to combat tumors

by Anne Trafton,Massachusetts Institute of TechnologyMIT researchers have identified a specialized subset of dendritic cells that help stimulate T cells to attack tumors. In this image, the blue

Updated on: May 07,2024

A stealthy way to combat tumors

by Anne Trafton,Massachusetts Institute of TechnologyMIT researchers have identified a specialized subset of dendritic cells that help stimulate T cells to attack tumors. In this image, the blue

Updated on:May 07,2024

Fracture risk down with adherence to bisphosphonates

For patients with an osteoporotic fracture, adherence to bisphosphonate treatment is associated with reduced fracture risk; and for veterans with rheumatoid arthritis, non-adherence to bisphosphonate

Updated on: March 24,2024

Fracture risk down with adherence to bisphosphonates

For patients with an osteoporotic fracture, adherence to bisphosphonate treatment is associated with reduced fracture risk; and for veterans with rheumatoid arthritis, non-adherence to bisphosphonate

Updated on:March 24,2024

BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLC

BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLCby International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public Domai

Updated on: September 25,2024

BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLC

BAY 2927088 demonstrates 'rapid, substantial and durable responses' in patients with HER2-mutant NSCLCby International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public Domai

Updated on:September 25,2024

MRI-guided Tx strategy not superior for rheumatoid arthritis

(HealthDay)—A magnetic resonance imaging (MRI)-guided treat-to-target strategy is not associated with improved disease activity remission rates for patients with rheumatoid arthritis (RA) in clinical

Updated on: May 08,2024

MRI-guided Tx strategy not superior for rheumatoid arthritis

(HealthDay)—A magnetic resonance imaging (MRI)-guided treat-to-target strategy is not associated with improved disease activity remission rates for patients with rheumatoid arthritis (RA) in clinical

Updated on:May 08,2024

A new toolkit to engineer safe and efficient therapeutic cells

by Stacie Dodgson and Françoise Chanut,Gladstone InstitutesGraphical abstract. Credit:Cell(2022). DOI: 10.1016/j.cell.2022.03.023Therapies based on engineered immune cells have recen

Updated on: May 07,2024

A new toolkit to engineer safe and efficient therapeutic cells

by Stacie Dodgson and Françoise Chanut,Gladstone InstitutesGraphical abstract. Credit:Cell(2022). DOI: 10.1016/j.cell.2022.03.023Therapies based on engineered immune cells have recen

Updated on:May 07,2024

Dupilumab cuts exacerbations in late-onset asthma

(HealthDay)—Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at

Updated on: April 15,2024

Dupilumab cuts exacerbations in late-onset asthma

(HealthDay)—Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at

Updated on:April 15,2024